John W McEvoy1, Yuan Chen1, Vijay Nambi1, Christie M Ballantyne1, A Richey Sharrett1, Lawrence J Appel1, Wendy S Post1, Roger S Blumenthal1, Kunihiro Matsushita1, Elizabeth Selvin2. 1. From Department of Epidemiology and Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD (J.W.M., Y.C., A.R.S., L.J.A., W.S.P., K.M., E.S.); Ciccarone Center for the Prevention of Heart Disease, Johns Hopkins University School of Medicine, Baltimore, MD (J.W.M., W.S.P., R.S.B.); Michael E. DeBakey Veterans Affairs Hospital, Houston, TX (V.M.); and Department of Medicine, Section of Cardiovascular Research, Baylor College of Medicine and Houston Methodist DeBakey Heart and Vascular Center, Houston, TX (V.M., C.M.B.). 2. From Department of Epidemiology and Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD (J.W.M., Y.C., A.R.S., L.J.A., W.S.P., K.M., E.S.); Ciccarone Center for the Prevention of Heart Disease, Johns Hopkins University School of Medicine, Baltimore, MD (J.W.M., W.S.P., R.S.B.); Michael E. DeBakey Veterans Affairs Hospital, Houston, TX (V.M.); and Department of Medicine, Section of Cardiovascular Research, Baylor College of Medicine and Houston Methodist DeBakey Heart and Vascular Center, Houston, TX (V.M., C.M.B.). eselvin@jhu.edu.
Abstract
BACKGROUND: The diagnosis of hypertension is often preceded by cardiac structural abnormalities. Thus, we assessed whether high-sensitivity cardiac troponin T (hs-cTnT), a marker of subclinical myocardial damage, can identify individuals at risk for hypertension or left ventricular hypertrophy. METHODS AND RESULTS: We studied 6516 Atherosclerosis Risk in Communities (ARIC) Study participants who were free of prevalent hypertension and cardiovascular disease at baseline (1990-1992). We examined the association of baseline hs-cTnT categories with incident diagnosed hypertension (defined by self-report of a diagnosis or medication use during a maximum of 19.9 years of follow-up) and with incident visit-based hypertension (defined by self-report, medication use, or measured blood pressure >140/90 mm Hg over 6 years). Relative to hs-cTnT <5 ng/L, adjusted hazard ratios for incident diagnosed hypertension were 1.16 (95% confidence interval, 1.08-1.25) for individuals with hs-cTnT of 5 to 8 ng/L, 1.29 (95% confidence interval, 1.14-1.47) for hs-cTnT of 9 to 13 ng/L, and 1.31 (95% confidence interval, 1.07-1.61) for hs-cTnT ≥14 ng/L (P for trend <0.001). Associations were stronger for incident visit-based hypertension. These associations were driven by higher relative hazard in normotensive people (compared with those with prehypertension; P for interaction=0.001). Baseline hs-cTnT was also strongly associated with incident left ventricular hypertrophy by electrocardiography over 6 years (eg, adjusted hazard ratio, 5.19 [95% confidence interval, 1.49-18.08] for hs-cTnT ≥14 versus <5 ng/L). Findings were not appreciably changed after accounting for competing deaths or adjusting for baseline blood pressure levels or N-terminal probrain natriuretic peptide. CONCLUSIONS: In an ambulatory population with no history of cardiovascular disease, hs-cTnT was associated with incident hypertension and risk of left ventricular hypertrophy. Further research is needed to determine whether hs-cTnT can identify people who may benefit from ambulatory blood pressure monitoring or hypertension prevention lifestyle strategies.
BACKGROUND: The diagnosis of hypertension is often preceded by cardiac structural abnormalities. Thus, we assessed whether high-sensitivity cardiac troponin T (hs-cTnT), a marker of subclinical myocardial damage, can identify individuals at risk for hypertension or left ventricular hypertrophy. METHODS AND RESULTS: We studied 6516 Atherosclerosis Risk in Communities (ARIC) Study participants who were free of prevalent hypertension and cardiovascular disease at baseline (1990-1992). We examined the association of baseline hs-cTnT categories with incident diagnosed hypertension (defined by self-report of a diagnosis or medication use during a maximum of 19.9 years of follow-up) and with incident visit-based hypertension (defined by self-report, medication use, or measured blood pressure >140/90 mm Hg over 6 years). Relative to hs-cTnT <5 ng/L, adjusted hazard ratios for incident diagnosed hypertension were 1.16 (95% confidence interval, 1.08-1.25) for individuals with hs-cTnT of 5 to 8 ng/L, 1.29 (95% confidence interval, 1.14-1.47) for hs-cTnT of 9 to 13 ng/L, and 1.31 (95% confidence interval, 1.07-1.61) for hs-cTnT ≥14 ng/L (P for trend <0.001). Associations were stronger for incident visit-based hypertension. These associations were driven by higher relative hazard in normotensive people (compared with those with prehypertension; P for interaction=0.001). Baseline hs-cTnT was also strongly associated with incident left ventricular hypertrophy by electrocardiography over 6 years (eg, adjusted hazard ratio, 5.19 [95% confidence interval, 1.49-18.08] for hs-cTnT ≥14 versus <5 ng/L). Findings were not appreciably changed after accounting for competing deaths or adjusting for baseline blood pressure levels or N-terminal probrain natriuretic peptide. CONCLUSIONS: In an ambulatory population with no history of cardiovascular disease, hs-cTnT was associated with incident hypertension and risk of left ventricular hypertrophy. Further research is needed to determine whether hs-cTnT can identify people who may benefit from ambulatory blood pressure monitoring or hypertension prevention lifestyle strategies.
Authors: Sunil K Agarwal; Christy L Avery; Christie M Ballantyne; Diane Catellier; Vijay Nambi; Justin Saunders; A Richey Sharrett; Josef Coresh; Gerardo Heiss; Ron C Hoogeveen Journal: Clin Chem Date: 2011-04-25 Impact factor: 8.327
Authors: James A de Lemos; Mark H Drazner; Torbjorn Omland; Colby R Ayers; Amit Khera; Anand Rohatgi; Ibrahim Hashim; Jarett D Berry; Sandeep R Das; David A Morrow; Darren K McGuire Journal: JAMA Date: 2010-12-08 Impact factor: 56.272
Authors: Justin T Saunders; Vijay Nambi; James A de Lemos; Lloyd E Chambless; Salim S Virani; Eric Boerwinkle; Ron C Hoogeveen; Xiaoxi Liu; Brad C Astor; Thomas H Mosley; Aaron R Folsom; Gerardo Heiss; Josef Coresh; Christie M Ballantyne Journal: Circulation Date: 2011-03-21 Impact factor: 29.690
Authors: Merel E Hellemons; Hiddo J Lambers Heerspink; Ron T Gansevoort; Dick de Zeeuw; Stephan J L Bakker Journal: J Hypertens Date: 2013-04 Impact factor: 4.844
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Roberta Florido; Alexandra K Lee; John W McEvoy; Ron C Hoogeveen; Silvia Koton; Mara Z Vitolins; Chetan Shenoy; Stuart D Russell; Roger S Blumenthal; Chiadi E Ndumele; Christie M Ballantyne; Corinne E Joshu; Elizabeth A Platz; Elizabeth Selvin Journal: Am J Epidemiol Date: 2019-12-31 Impact factor: 4.897
Authors: Amer I Aladin; Mahmoud Al Rifai; Shereen H Rasool; Zeina Dardari; Joseph Yeboah; Khurram Nasir; Matthew J Budoff; Bruce M Psaty; Roger S Blumenthal; Michael J Blaha; John W McEvoy Journal: Am J Cardiol Date: 2017-10-24 Impact factor: 2.778
Authors: Ambarish Pandey; Kershaw V Patel; Wanpen Vongpatanasin; Colby Ayers; Jarett D Berry; Robert J Mentz; Michael J Blaha; John W McEvoy; Paul Muntner; Muthiah Vaduganathan; Adolfo Correa; Javed Butler; Daichi Shimbo; Vijay Nambi; Christopher deFilippi; Stephen L Seliger; Christie M Ballantyne; Elizabeth Selvin; James A de Lemos; Parag H Joshi Journal: Circulation Date: 2019-11-11 Impact factor: 29.690
Authors: Junichi Ishigami; Ron C Hoogeveen; Christie M Ballantyne; Aaron R Folsom; Josef Coresh; Elizabeth Selvin; Kunihiro Matsushita Journal: Am J Epidemiol Date: 2019-12-31 Impact factor: 4.897
Authors: Jonathan Rubin; Kunihiro Matsushita; Mariana Lazo; Christie M Ballantyne; Vijay Nambi; Ron Hoogeveen; A Richey Sharrett; Roger S Blumenthal; Josef Coresh; Elizabeth Selvin Journal: Clin Biochem Date: 2016-03-11 Impact factor: 3.281
Authors: John W McEvoy; Natalie Daya; Faisal Rahman; Ron C Hoogeveen; Roger S Blumenthal; Amil M Shah; Christie M Ballantyne; Josef Coresh; Elizabeth Selvin Journal: JAMA Date: 2020-01-28 Impact factor: 56.272
Authors: Jacqueline D Wright; Aaron R Folsom; Josef Coresh; A Richey Sharrett; David Couper; Lynne E Wagenknecht; Thomas H Mosley; Christie M Ballantyne; Eric A Boerwinkle; Wayne D Rosamond; Gerardo Heiss Journal: J Am Coll Cardiol Date: 2021-06-15 Impact factor: 27.203